Pharmacogenomics of statin therapy: any new insights in efficacy or safety?

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?

PURPOSE OF REVIEW: To examine the current evidence concerning the effects of genetic variation on statin-related low-density lipoprotein cholesterol reductions, clinical efficacy, and adverse events and the relevance for patient care. RECENT FINDINGS: Recent years have seen the emergence of large-sc...

Полное описание

Библиографические подробности
Главные авторы:	Hopewell, J, Reith, C, Armitage, J
Формат:	Journal article
Язык:	English
Опубликовано:	Lippincott Williams and Wilkins 2014

Схожие документы

Interpretation of the evidence for the efficacy and safety of statin therapy
по: Collins, R, и др.
Опубликовано: (2016)

Safety and efficacy of statins - Authors' reply
по: Collins, R, и др.
Опубликовано: (2017)

Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials
по: Cholesterol Treatment Trialists' Collaboration, и др.
Опубликовано: (2019)

Pharmacogenomics Statins: Biomarkers for Clinical Prediction
по: Herni Suprapti
Опубликовано: (2018-09-01)

The safety of statins in clinical practice.
по: Armitage, J
Опубликовано: (2007)

The Genetic Blueprint of Cardiovascular Therapy: Pharmacogenomics for Improved Efficacy and Safety
по: Nikhilesh Andhi, и др.
Опубликовано: (2024-08-01)

Role of Pharmacogenomics in Statin Responsiveness; A Review
по: Niusha behdad, и др.
Опубликовано: (2015-12-01)

Role of pharmacogenomics in Statin Responsiveness; A review
по: Niusha behdad, и др.
Опубликовано: (2015-12-01)

Misrepresentation of statin safety evidence.
по: Armitage, J, и др.
Опубликовано: (2014)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
по: Hopewell, J, и др.
Опубликовано: (2011)

Statins: are any questions unanswered?
по: Kearney, P, и др.
Опубликовано: (2006)

Intensive statin therapy in India: Demonstrating efficacy and safety
по: Michael H. Davidson, MD, FACC, FNLA
Опубликовано: (2016-11-01)

Moderate-intensity statin therapy. Efficacy and safety issues
по: N. G. Gogolashvili
Опубликовано: (2023-07-01)

Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry
по: Han Joon Bae, и др.
Опубликовано: (2020-03-01)

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
по: Reith, CA, и др.
Опубликовано: (2024)

Pharmacogenomics And Hypertension: Current Insights
по: Oliveira-Paula GH, и др.
Опубликовано: (2019-11-01)

STATIN GENERICS: EFFICACY AND SAFETY RATIO
по: V. P. Voronina, и др.
Опубликовано: (2016-01-01)

STATIN GENERICS: EFFICACY AND SAFETY RATIO
по: V. P. Voronina, и др.
Опубликовано: (2016-01-01)

Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
по: Catarina Correia, и др.
Опубликовано: (2022-08-01)

Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations
по: Dan Li, и др.
Опубликовано: (2020-10-01)

Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins
по: Jenna E. van Leeuwen, и др.
Опубликовано: (2022-10-01)

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
по: Mihaylova, B, и др.
Опубликовано: (2016)

Efficacy and safety of statin therapy in multimorbid outpatients with very high cardiovascular risk
по: N. V. Izmozherova, и др.
Опубликовано: (2020-07-01)

Does the benefit from statin therapy extend beyond 5 years?
по: Bulbulia, R, и др.
Опубликовано: (2013)

Does the benefit from statin therapy extend beyond 5 years?
по: Bulbulia, R, и др.
Опубликовано: (2013)

Editorial: Insights in pharmacogenetics and pharmacogenomics: 2023
по: José A. G. Agúndez, и др.
Опубликовано: (2025-01-01)

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
по: José A. G. Agúndez, и др.
Опубликовано: (2022-04-01)

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
по: Stojiljkovic Maja, и др.
Опубликовано: (2012-09-01)

Estimating the efficacy of pharmacogenomics over a lifetime
по: Zhan Ye, и др.
Опубликовано: (2023-10-01)

Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing.
по: James S Floyd, и др.
Опубликовано: (2019-01-01)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
по: Hopewell, J, и др.
Опубликовано: (2009)

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics
по: Wei Zhang, и др.
Опубликовано: (2008-01-01)

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics
по: Wei Zhang, и др.
Опубликовано: (2008-02-01)

Individual participant data meta-analysis of new-onset and worsening diabetes mellitus in large-scale randomized double-blind trials of statin therapy
по: Preiss, D, и др.
Опубликовано: (2022)

The Pharmacogenomics of Anti-Hypertensive Therapy
по: Sandosh Padmanabhan, и др.
Опубликовано: (2010-06-01)

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
по: Lally J, и др.
Опубликовано: (2016-11-01)

Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses
по: Hai-Yan He, и др.
Опубликовано: (2017-04-01)

Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
по: Mihaylova, B, и др.
Опубликовано: (2024)

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
по: Reith, C
Опубликовано: (2022)

Clinical efficacy and safety of statins in managing cardiovascular risk
по: Navin K Kapur, и др.
Опубликовано: (2008-04-01)